BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/28/2024 4:34:22 AM | Browse: 107 | Download: 737
 |
Received |
|
2024-08-01 08:56 |
|
Peer-Review Started |
|
2024-08-01 08:56 |
|
First Decision by Editorial Office Director |
|
2024-08-21 10:12 |
|
Return for Revision |
|
2024-08-21 10:12 |
|
Revised |
|
2024-08-30 04:19 |
|
Publication Fee Transferred |
|
2024-09-04 00:36 |
|
Second Decision by Editor |
|
2024-09-03 02:43 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-09-03 08:26 |
|
Articles in Press |
|
2024-09-03 08:26 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-09-18 23:41 |
|
Publish the Manuscript Online |
|
2024-09-28 04:34 |
| ISSN |
1948-9366 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Zhen-Yu Ding, Ying Piao, Tong Jiang, Juan Chen, Yi-Nuo Wang, Hui-Ying Yu and Zhen-Dong Zheng |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Zhen-Dong Zheng, PhD, Chief Physician, Department of Oncology, General Hospital of Northern Theater Command, No. 83 Wenhua Road, Shenyang 110016, Liaoning Province, China. zzd_oncologist@163.com |
| Key Words |
Analysis of variables affecting outcomes; Cellular immunotherapy; Chemotherapy; Colorectal cancer; Clinical effects |
| Core Tip |
Adjuvant postoperative therapy for colorectal cancer (CRC) maximizes surgical outcomes while significantly reducing CRC-related mortality. This study analyzes the efficacy of the XELOX regimen combined with dendritic cell-cytokine-induced killer (DC-CIK) cell immunotherapy for postoperative CRC patients and the mediating variables, aiming to provide a useful clinical reference to optimize the efficacy of postoperative CRC treatment. Through a comparative analysis of the XELOX chemotherapy regimen vs XELOX regimen plus DC-CIK immunotherapy therapy across multiple outcome and safety indices, including efficacy, adverse event rates, serum tumor marker levels, and T-cell subset levels, the combination regimen is confirmed to offer greater efficacy than a chemotherapy regimen alone, enhancing patient immunity, increasing physiological antitumor activity, and providing improved treatment safety. |
| Publish Date |
2024-09-28 04:34 |
| Citation |
Ding ZY, Piao Y, Jiang T, Chen J, Wang YN, Yu HY, Zheng ZD. Effects of postoperative treatment with chemotherapy and cellular immunotherapy on patients with colorectal cancer. World J Gastrointest Surg 2024; 16(10): 3202-3210 |
| URL |
https://www.wjgnet.com/1948-9366/full/v16/i10/3202.htm |
| DOI |
https://dx.doi.org/10.4240/wjgs.v16.i10.3202 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
